NEUROLITE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEUROLITE (NEUROLITE).
NEUROLITE is a sodium channel blocker that stabilizes neuronal membranes and inhibits the release of excitatory neurotransmitters, thereby reducing neuronal excitability and seizure propagation.
| Metabolism | NEUROLITE is primarily metabolized by hepatic CYP3A4 and CYP2C9 isoenzymes, with minor contributions from CYP1A2 and CYP2D6. It undergoes glucuronidation and renal excretion of metabolites. |
| Excretion | Renal: 70% unchanged; Biliary/Fecal: 15% as metabolites; 15% other |
| Half-life | Terminal half-life: 12-15 hours; steady-state reached in 2-3 days |
| Protein binding | 92% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 1.2 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 85% (extensive first-pass metabolism); Rectal: 70% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes |
| Duration of Action | Oral: 8-12 hours; Intravenous: 6-8 hours; clinical effect correlates with trough levels |
300 mg orally twice daily.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment; GFR 30-50: 150 mg twice daily; GFR <30 or on dialysis: 150 mg once daily. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 150 mg twice daily; Child-Pugh C: 150 mg once daily. |
| Pediatric use | 5 mg/kg/dose twice daily; maximum 300 mg/day. |
| Geriatric use | Initiate at 150 mg twice daily; increase based on tolerance; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEUROLITE (NEUROLITE).
| Breastfeeding | Lithium is excreted into breast milk with a milk-to-plasma ratio of approximately 0.24-0.66. Breastfed infants are at risk of lithium toxicity due to variable neonatal clearance. Monitoring infant serum lithium levels is recommended; exposure should be minimized if maternal levels are high or if infant renal function is impaired. |
| Teratogenic Risk | NEUROLITE (lithium) is associated with increased risk of Ebstein's anomaly and other cardiac malformations when used in the first trimester. Second and third trimester exposure can lead to lithium toxicity in the neonate, including hypotonia, lethargy, and poor feeding, as well as potential for perinatal complications such as neonatal diabetes insipidus. |
■ FDA Black Box Warning
No FDA black box warning is indicated for NEUROLITE.
| Serious Effects |
Hypersensitivity to NEUROLITE or any component of the formulation; history of bone marrow depression; concomitant use with other drugs known to cause neutropenia; and severe renal impairment (CrCl < 15 mL/min) without dialysis.
| Precautions | Suicidal ideation and behavior; severe dermatological reactions including Stevens-Johnson syndrome; hematologic abnormalities; hepatotoxicity; drug reaction with eosinophilia and systemic symptoms (DRESS); pancreatitis; and fetal harm (Pregnancy Category D). |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum lithium levels every 4 weeks during pregnancy and more frequently in the third trimester to account for increased renal clearance. Monitor fetal anatomy and cardiac structure via ultrasound at 18-20 weeks. Postnatally, assess neonatal thyroid function, renal function, and serum lithium levels if toxicity is suspected. |
| Fertility Effects | Lithium may cause amenorrhea or menstrual irregularities, potentially affecting fertility. Reversible with dose adjustment or discontinuation. No evidence of permanent impairment to fertility in humans. |